FDA's critical path initiative: a perspective on contributions of biostatistics (Q5122840)
From MaRDI portal
!
This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use the normal view instead:
scientific article; zbMATH DE number 7251464
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | No label defined |
||
| English | FDA's critical path initiative: a perspective on contributions of biostatistics |
scientific article; zbMATH DE number 7251464 |
Statements
FDA's Critical Path Initiative: A Perspective on Contributions of Biostatistics (English)
0 references
24 September 2020
0 references
adaptive study designs
0 references
clinical trial simulation
0 references
FDA critical path
0 references
guidance development
0 references
multiple endpoints
0 references
missing data
0 references
non-inferiority trials
0 references
quantitative risk/safety assessment
0 references
regulatory biostatistics
0 references
0.7357738614082336
0 references
0.7140556573867798
0 references
0.7112748026847839
0 references
